bv-101
Gene therapyexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 12, 2022 (NCT05541627)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Cholesterol 24-hydroxylaseSupplementation
supplementation - CYP46A1
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05541627 | Phase 1/Phase 2 (Phase 2) | Oct 12, 2022 | Asklepios BIoPharmaceutical |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Asklepios BIoPharmaceutical | For profit | 1 | 1 | 1 | 2022 |
1 organizations
Page 1 / 1